AY-9944

Research use only, not for human use.

AY-9944 is a cholesterol biosynthesis inhibitor that targets the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme (IC50=13 nM).

AY-9944 is a cholesterol biosynthesis inhibitor that targets the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme (IC50=13 nM), attenuates of Smoothened-dependent and -independent Hh signaling; has been used to recapitulate phenotypes of Smith-Lemli-Opitz syndrome in animal model.

Cell Viability Assay Cell Line:Human foreskin keratinocytes Concentration:1 μg/mL Incubation Time:15 hours Result:Inhibited the synthesis of cholesterol and desmosterol, but increased 7-dehydrocholesterol and zymosterol synthesis.

Animal Model:Long–Evans hooded rats.Dosage:7.5 mg/kg Administration:Subcutaneous injection; 7.5 mg/kg every 6 days once; from postnatal day 2 to postnatal day 20 Result:Reduced brain cholesterol and increased 7-dehydrocholesterol in all brain regions of rats till the treatment stopped for 400 days and showed a more severe effect on the change of sterols in plasma and liver of female rats.

AY9944

GPCR/G Protein

Hedgehog (Hh)

Hedgehog (Hh)

——

——

366-93-8

464.3

C22H28Cl2N2 ? 2HCl

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (10.77 mM)

ClC1=CC=CC=C1CNC[C@H]2CC[C@H](CNCC3=CC=CC=C3Cl)CC2.Cl.Cl

trans-N,N-bis[2-Chlorophenylmethyl]-1,4-cyclohexanedimethanamine dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years